It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for PTC Therapeutics Inc (PTCT) shows that investor sentiment remained same, with the stock’s consolidated last price to $20.46. The PTC Therapeutics Inc has recorded 18,152 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
PTC Therapeutics Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $20.46 and fluctuated between $20.56 as its day high and $19.80 as its day low. The current market capitalization of PTC Therapeutics Inc is $1.54B. A total of 0.78 million shares were traded on the day, compared to an average of 1.39M shares.
Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, PTCT has seen 2 BUY and 2 SELL insider trades, representing the acquisition of 11,666 and the disposition of 11,666 shares. Over the last 12 months, there were 41 BUYs and 81 SELLs from insiders. Insiders purchased 447,938 shares during that period but sold 224,316.
In the most recent transaction, Young Alethia sold 11,666 shares of PTCT for 39.86 per share on Sep 06. After the transaction, the Director now owns 9,067 company shares. In a previous transaction on Jun 07, SCHMERTZLER MICHAEL sold 1,000 shares at 44.86 per share. PTCT shares that Director owns now total 116,766.
Among the insiders who sold shares, Reeve Emma disposed of 2,652 shares on May 23 at a per-share price of $59.53. This resulted in the Director holding 7,200 shares of PTCT after the transaction. In another insider transaction, Reeve Emma sold 7,116 shares at $59.53 per share on May 22. Company shares held by the Director now total 7,200.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for PTCT in the last 3 months, the mean price target is $28.08 with high estimates of $51.00 and low estimates of $17.00. In terms of 52-week highs and lows, PTCT has a high of $59.84 and a low of $17.53.
As of this writing, PTCT has an earnings estimate of $0.31 per share for the current quarter. EPS was calculated based on a consensus of 13 estimates, with a high estimate of $1.47 per share and a lower estimate of -$2.41. The company reported an EPS of -$2.66 in the last quarter, which was -114.50% lower than expectations of -$1.24.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. PTCT’s latest balance sheet shows that the firm has $773.38M in Cash & Short Term Investments as of fiscal 2021. There were $431.43M in debt and $509.35M in liabilities at the time. Its Book Value Per Share was -$8.89, while its Total Shareholder’s Equity was $1.44M.
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for PTCT is Buy with a score of 3.07.